Maria Swiatkowska
Overview
Explore the profile of Maria Swiatkowska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ponamarczuk H, Swiatkowska M, Popielarski M
Front Biosci (Landmark Ed)
. 2025 Jan;
30(1):26542.
PMID: 39862083
Background: Androgenic anabolic steroids (AASs) are synthetic drugs structurally related to testosterone, with the ability to bind to androgen receptors. Their uncontrolled use by professional and recreational sportspeople is a...
2.
Salifu M, Bets I, Gdula A, Braun M, Watala C, Beckles D, et al.
J Vasc Interv Radiol
. 2023 Oct;
35(2):285-292.
PMID: 37871832
Purpose: To determine whether inhibition of the F11 receptor/JAM-A (F11R) using F11R-specific antagonist peptide 4D results in inhibition of smooth muscle cell (SMC) proliferation and migration in vivo, known as...
3.
Bednarek R, Wojkowska D, Braun M, Watala C, Salifu M, Swiatkowska M, et al.
Cancer Cell Int
. 2023 Aug;
23(1):160.
PMID: 37563645
Background: The F11R/JAM-A cell adhesion protein was examined as the therapeutic target in triple negative breast cancer (TNBC) with the use of the peptide antagonist to F11R/JAM-A, that previously inhibited...
4.
Czubak-Prowizor K, Babinska A, Swiatkowska M
Mol Cell Biochem
. 2021 Sep;
477(1):79-98.
PMID: 34533648
The F11 Receptor (F11R), also called Junctional Adhesion Molecule-A (JAM-A) (F11R/JAM-A), is a transmembrane glycoprotein of the immunoglobulin superfamily, which is mainly located in epithelial and endothelial cell tight junctions...
5.
Gdula A, Swiatkowska M
Microvasc Res
. 2021 Jun;
138:104218.
PMID: 34182003
Backgrounds And Aims: To address the problem of resistance to standard antiplatelet therapy in some patients, our team proposed a purinoceptor-dependent dual therapy. Its efficacy is also determined by the...
6.
Gdula A, Swiatkowska M
J Cardiovasc Pharmacol
. 2020 Jun;
76(3):349-359.
PMID: 32569015
In the recent years, the awareness of the role purinergic signaling plays as a therapeutic target has increased considerably. The purinoceptor allows the action of extracellular nucleotides (P2 receptors) and...
7.
Babinska A, Clement C, Li Y, Wzorek J, Przygodzki T, Talar M, et al.
Data Brief
. 2020 May;
30:105516.
PMID: 32395574
The data in this article focus on the F11 Receptor (F11R/JAM-A; Junctional Adhesion Molecule-A; JAM-A, F11R), a cell adhesion protein constitutively expressed on the membrane surface of circulating platelets and...
8.
Popielarski M, Ponamarczuk H, Stasiak M, Gdula A, Bednarek R, Wolska N, et al.
Biochem Biophys Res Commun
. 2020 Apr;
526(3):756-763.
PMID: 32265027
Secretion of PDI from platelets and endothelial cells is an important step of all thrombotic events. In the absence of extracellular PDI thrombus formation and fibrin generation may be impaired....
9.
Bednarek R, Selmi A, Wojkowska D, Karolczak K, Popielarski M, Stasiak M, et al.
Breast Cancer Res Treat
. 2019 Oct;
179(2):325-335.
PMID: 31650345
Purpose: To examine the involvement of the F11R/JAM-A protein in breast cancer metastasis, we utilized the F11R/JAM-A antagonistic peptide 4D (P4D) in experiments of transendothelial migration (TEM) of breast cancer...
10.
Popielarski M, Ponamarczuk H, Stasiak M, Watala C, Swiatkowska M
Am J Cancer Res
. 2019 Sep;
9(8):1554-1582.
PMID: 31497343
Cancer metastasis involves the adhesion of cancer cells to the endothelium. This process can be mediated by integrins which are surface receptors responsible for interactions with ECM proteins. Integrins β...